Bibliography
- Deng H, Liu R, Ellenmeier W, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996;381:661-6
- Dragic T, Litwin V, Allaway GP, et al. HIV-1 entry into CD4+ cells is mediated by chemokine receptor CC-CKR-5. Nature 1996;381:667-73
- Cocchi F, Devico AL, Garzino DA, et al. Identification of RANTES, MIP1α and MIP1β as the major HIV suppressive factors produced by CD8+ T-cells. Science 1995;270:1811-15
- Lederman MM, Veazey RS, Offord R, et al. Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science 2004;306:485-7
- Feng Y, Broder CC, Kennedy PE, Berger E. HIV-1 entry co-factor: functional cDNA cloning of a seven-transmembrane G protein-coupled receptor. Science 1996;272:872-7
- Doranz BJ, Rucker J, Yi Y, et al. A dual-tropic primary HIV-1 isolate that uses fusin and the β-chemokine receptors CKR5, CKR3 and CKR2b as fusion cofactors. Cell 1996;85:1149-58
- Chackerian B. Virus-like particles: flexible platforms for vaccine development. Exp Rev Vaccines 2007;6:381-90
- Jennings GT, Bachmann MF. Immunodrugs: Therapeutic VLP-based vaccines for chronic diseases. Ann Rev Pharmacol toxicol 2009;49:303-26
- Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 co-receptor accounts for resistance of some multiply exposed individuals to HIV-1 infection. Cell 1996;86:367-77
- Michael NL, Nelson JA, Kewalramani VN, et al. Exclusive and persistent use of the entry coreceptor CXCR4 by human immunodeficiency virus type 1 from a subject homozygous for CCR5 delta 32. J Virol 1998;2:6040-47
- Marmor M, Sheppard HW, Donnell D. et al. Homozygous and heterozygous CCR5-delta 32 genotypes are associated with resistance to HIV infection. J Acquir Inf Defic Syndr 2001;27:472-81
- Lederman MM, Penn-Nicholson A, Cho M, Mosier D. Biology of CCR5 and its role in HIV infection and treatment. JAMA 2006;296:815-26
- Tachibana K, Hirota S, Iizasa H, et al. The chemokine receptor CXCR4 is essential for vascularisation of the gastrointestinal tract. Nature 1998;393:524-5
- Arteaga HJ, Hinkula J, van Dijk-Härd, et al. Choosing CCR5 or Rev siRNA in HIV-1. Nat Biotechnol 2003;21:230-1
- Qin XF, An DS, Chen IS, Baltimore D. Inhibiting HIV-1 infection in human T-cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc Natl Acad Sci USA 2003;100:183-8
- Simmons G, Clapham P, Picard L, et al. Potential inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science 1997;276:276-9
- Baba M, Nishimura O, Kanzaki N, et al. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci USA 1999;96:5698-703
- Yang A-G, Bai X, Yao C, Chen S-Y. Phenotypic knock out of HIV type 1 chemokine coreceptor CCR5 by intrakines as potential therapeutic approach for HIV-1 infection. Proc Natl Acad Sci USA 1997;94:11567-72
- Steinberger P, Andris-Widhopf J, Büler B, et al. Functional deletion of the CCR5 receptor by intracellular immunization produces cells that are refractory to CCR5-dependent HIV-1 infection and cell fusion. Proc Natl Acad Sci USA 2000;97:805-10
- Trkola A, Ketas TJ, Nagashima KA, et al. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140. J Virol 2001;75:579-88
- Castagna A, Biswas P, Beretta A, Lazzarin A. The appealing story of HIV inhibitors: from discovery of biological mechanisms to drug discovery. Drugs 2005;65:879-904
- Jacobson J, Saag MS, Thompson MA, et al. Antiviral activity of single dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults. J Infect Dis 2008;198:1345-52
- Paterlini GM. Structure modeling of the chemokine receptor CCR5: implications for ligand binding and selectivity. Biophys J 2002;83:3012-31
- Dragic T, Trkola A, Lin SW, et al. Amino-terminal substitutions in the CCR5 coreceptor impair gp120 binding and human immunodeficiency virus type 1 entry. J Virol 1998;72:279-85
- Alkhatib G. Ahuya SS, Light D, et al. CC chemokine receptor 5-mediated signaling and HIV-1 Co-receptor activity share common structural determinants. Critical residues in the third extracellular loop support HIV-1 fusion. J Biol Chem 1997;272:19771-6
- Blanpain C, Doranz BJ, Vakili J, et al. Multiple charged and aromatic residues in CCR5 amino-terminal domain are involved in high affinity binding of both chemokines and HIV-1 Env protein. J Biol Chem 1999;274:34719-27
- Doranz BJ, Lu ZH, Rucker J, et al. Two distinct CCR5 domains can mediate coreceptor usage by human immunodeficiency virus type 1. J Virol 1997;71:6305-14
- Hill CM, Kwon D, Jones M, et al. The amino terminus of human CCR5 is required for its function as a receptor for diverse human and simian immunodeficiency virus envelope glycoproteins. Virology 1998;248:357-71
- Lu Z, Berson JF, Chen Y, et al. Evolution of HIV-1 coreceptor usage through interactions with distinct CCR5 and CXCR4 domains. Proc Natl Acad Sci USA 1997;94:6426-31
- Rabut GE, Konner JA, Kajumo F, et al. Alanine substitutions of polar and nonpolar residues in the amino-terminal domain of CCR5 differently impair entry of macrophage- and dualtropic isolates of human immunodeficiency virus type 1. J Virol 1998;72:3464-8
- Rucker J, Samson M, Doranz BJ, et al. Regions in beta-chemokine receptors CCR5 and CCR2b that determine HIV-1 cofactor specificity. Cell 1996;87:437-46
- Agrawal L, Vanhorn-Ali Z, Berger EA, Alkhatib G. Specific inhibition of HIV-1 co-receptor activity by synthetic peptides corresponding to the predicted extracellular loops of CCR5. Blood 2004;103:1211-7
- Misumi S, Nakajima R, Takamune N, Shoji S. A cyclic dodecapeptide-multiple-antigen peptide conjugate from the undecapeptidyl arch (from Arg(168) to Cys(178)) of extracellular loop 2 in CCR5 as a novel human immunodeficiency virus type 1 vaccine. J Virol 2001;75:11614-20
- Lehner T, Doyl C, Wang Y, et al. Immunogenicity of the extracellular domains of C-C chemokine receptor 5 and the in vitro effects on simian immunodeficieny virus or HIV infectivity. J Immunol 2001;166:7446-55
- Samson M, LaRosa G, Libert F, et al. The second extracellular loop of CCR5 is the major determinant of ligand specificity. J Biol Chem 1997;272:24934-41
- Bachmann M, Tissot A, Jegerlehner A, et al. Antigen conjugates and uses thereof. WO 2006/134125; 2006
- Peabody D, Chackerian B. A virus-like platform for rapid vaccine discovery. WO 2008/024427; 2008
- Peabody DS, Manifold-Wheeler B, Medford A, et al. Immunogenic display of diverse peptides on virus-like particles of RNA phage MS2. J Mol Biol 2008;380:252-63
- Chackerian B, Lowy DR, Schiller JT. Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles. Proc Natl Acad Sci USA 1999;96:2373-78
- Chackerian B, Briglio L, Albert P, et al. Induction of autoantibodies to CCR5 in macaques and subsequent effects upon challenge with an R5-tropic simian/human immunodeficiency virus. J Virol 2004;78:4037-47
- Wolfgang R, Bachmann M. Molecular antigen array. WO 02056905; 2002
- Trkola A, Mathiews J, Gordon C, et al. A cell line based neutralisation assay for primary human immunodeficiency virus type 1 isolates that use either the CCR5 or the CXCR4 coreceptor. J Virol 1999;73:8966-74
- Moncunill G, Armand-Ugòn M, Pauls E, et al. HIV-1 escape to CCR5 coreceptor antagonism through selection of CXCR4-using variants in vitro. AIDS 2008;22:23-31
- Telenti A. Safety concerns about CCR5 as an antiviral target. Curr Opin HIV AIDS 2009;4:131-5
- Lim JK, Louie CY, Glaser C, et al. Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: a meta-analysis of 4 cohorts in the US epidemic. J Infect Dis 2008;197:262-5
- Lalani AS, Masters J, Zeng W. Use of chemokine receptors by poxviruses. Science 1999;286:1968-71